Immunology of Diabetes IV: Progress in Our Understanding Volume 1079 published October 2006 Ann. N.Y. Acad. Sci. 1079: 369–373 (2006). doi: 10.1196/annals.1375.057 Copyright © 2006 by the New York Academy of Sciences description | purchase this volume

This Volume Table of Contents Description This Article Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by YOUNG, D. L Articles by SHODA, L. K.M Search for Related Content PubMed PubMed Citation Articles by YOUNG, D. L Articles by SHODA, L. K.M

Part VIII. Prediction and Prevention

Mechanisms Mediating Anti-CD3 Antibody Efficacy

Insights from a Mathematical Model of Type 1 Diabetes

Key Words: diabetes remission • cells • antigen presenting cells • 145-2C11 • systems biology • glucose control

Anti-CD3 antibody therapy, a promising clinical approach for the treatment of type 1 diabetes (T1D), was investigated using a mathematical model of T1D in the female nonobese diabetic (NOD) mouse. Analyses of model simulation results indicate that, in addition to the known direct effects of anti-CD3 antibody on T lymphocytes, two additional mechanisms are required for sustained disease remission: (a) rapid regrowth of healthy cells following clearance of islet inflammation and (b) enhanced regulatory T cell activity and/or phenotypic changes in antigen presenting cells (APCs) that promote a stable regulatory environment in the pancreas.

©2006 New York Academy of Sciences, all rights reserved.
Privacy Policy and Disclaimer.

7 World Trade Center, 250 Greenwich St, 40th Fl, New York, NY 10007-2157
info{at}nyas.org | 212.298.8600